CD8A and melanoma: In melanoma patients, both ipilimumab and nivolumab monotherapy readily expand activated PD-1+ CD8+ cells in the peripheral blood; however, combination therapy expanded both PD-1+CD8+ cells and resting PD-1-CD8+ cells [122].